drugset / Trial / NCT01016808

Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients

NCT01016808

Phase 3 Completed 522 enrolled QRxPharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, multicenter, fixed dose factorial study of Q8003 12 mg/8 mg versus its individual morphine sulfate and oxycodone hydrochloride components for the management of acute moderate to severe postoperative pain following bunionectomy surgery.

Timeline

Start
2009-12
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 12 mg
Comparator Oxycodone Other / unclassified 8 mg

Indications

No indication recorded.